

REF: MDOL/CS-SE/2025-26/033

5<sup>th</sup> November, 2025

To,

Listing Department  
**BSE Ltd**  
1<sup>st</sup> Floor, New Trade Wing,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001

Listing Department  
**National Stock Exchange of India  
Limited**

“Exchange Plaza”, 5<sup>th</sup> Floor,  
Plot No. C-1, Block G,  
Bandra - Kurla Complex,  
Bandra(E), Mumbai – 400 051

**Scrip Code: 532637**

**Symbol: MANGALAM**

**Subject: Intimation of Board Meeting to be held on Thursday, November 13, 2025**

Dear Sir / Madam,

Pursuant to Regulation 29 and other applicable provisions, if any, of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, we are pleased to inform that a meeting of the Board of Directors of the Company is scheduled to be held on **Thursday, November 13, 2025** at the registered office of the Company situated at 3<sup>rd</sup> Floor, Rupam Building, 239, P.D' Mello Road, Near G.P.O., Mumbai – 400001, Maharashtra, India *inter-alia* to consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the Quarter ended September 30, 2025 (Q2).

Further, in terms of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and in accordance with Company's internal code of conduct for prevention of insider trading, the Trading Window for dealing in the securities of the Company has already been closed for Directors / Officers and designated employees of the Company from October 1, 2025 and shall remain closed till the expiry of 48 hours from the announcement / declaration of the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended September 30, 2025 (Q2).

Kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mangalam Drugs & Organics Limited**

**Govardhan M. Dhoot**

Managing Director

**DIN: 01240086**